Loading...
•
Jun 30, 2023
Fulgent Q2 2023 Earnings Report
Fulgent reported second quarter 2023 financial results with a total revenue of $68 million and record core revenue of $67 million, representing a 48% year-over-year growth.
Key Takeaways
Fulgent Genetics reported a total revenue of $68 million for Q2 2023. Core revenue grew 48% year-over-year to $67 million. The company experienced a GAAP loss of $11.2 million, or $0.38 per share, and a non-GAAP loss of $2.4 million, or $0.08 per share.
Total revenue was $68 million.
Core revenue grew 48% year-over-year to $67 million.
GAAP loss was $11.2 million, or $0.38 per share.
Non-GAAP loss was $2.4 million, or $0.08 per share.
Revenue by Segment
Forward Guidance
Fulgent expects core revenue of approximately $65 million for the third quarter of 2023 and now expects core revenue of approximately $260 million, a GAAP loss of approximately $2.15 per share and a Non-GAAP loss of approximately $0.95 per share for the full year 2023.
Positive Outlook
- Core Revenue of approximately $65 million for Q3 2023
- Core Revenue of approximately $260 million for full year 2023
Challenges Ahead
- GAAP loss of approximately $2.15 per share for full year 2023
- Non-GAAP loss of approximately $0.95 per share for full year 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...